Eads & Heald Wealth Management Sells 467 Shares of Danaher Co. (NYSE:DHR)

Eads & Heald Wealth Management reduced its position in shares of Danaher Co. (NYSE:DHR) by 5.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,918 shares of the conglomerate’s stock after selling 467 shares during the period. Eads & Heald Wealth Management’s holdings in Danaher were worth $2,201,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of DHR. Vanguard Group Inc. boosted its position in Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after acquiring an additional 4,163,657 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Danaher by 2.4% in the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after purchasing an additional 139,989 shares in the last quarter. Capital Research Global Investors boosted its holdings in Danaher by 1.0% during the first quarter. Capital Research Global Investors now owns 5,125,470 shares of the conglomerate’s stock worth $1,279,932,000 after purchasing an additional 52,679 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Danaher by 2.6% in the second quarter. Dimensional Fund Advisors LP now owns 3,398,649 shares of the conglomerate’s stock valued at $849,195,000 after purchasing an additional 85,081 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Danaher by 22.7% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 3,047,728 shares of the conglomerate’s stock valued at $761,475,000 after buying an additional 563,546 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Leerink Partners increased their price objective on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Raymond James decreased their price target on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Stephens reiterated an “overweight” rating and set a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a report on Thursday. Finally, TD Cowen boosted their target price on shares of Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $287.16.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 11.10% of the company’s stock.

Danaher Price Performance

Danaher stock opened at $247.82 on Friday. The company has a market capitalization of $178.99 billion, a price-to-earnings ratio of 47.29, a PEG ratio of 4.45 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 12 month low of $190.95 and a 12 month high of $281.70. The stock’s 50 day moving average is $266.95 and its 200-day moving average is $260.37.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the prior year, the firm posted $2.02 EPS. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. Equities research analysts expect that Danaher Co. will post 7.51 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were paid a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.